Absorption and distribution<unk>  is available as a 2:1 fixed combination (such that a 1.5-g dose of<unk>  is composed of 1 g of<unk>  and 500 mg of<unk> .<unk>  is administered intravenously. For both<unk>  and<unk> , the peak plasma concentration occurs immediately after a 60-minute infusion, with a time to maximum concentration of approximately one hour. The binding of<unk>  to human plasma proteins is approximately 16% to 21%, while the binding of<unk>  is approximately 30%. The mean steady-state volume of distribution in healthy adult males after a single 1.5 g IV dose is 13.5 L for<unk>  and 18.2 L for<unk> , which is similar to extracellular fluid volume. Tissue distribution of ceftalozone-tazobactam is rapid and shows good penetration into the lung, rendering it an ideal treatment for bacterial pneumonia. Metabolism and elimination The metabolism and excretion of<unk>  are similar to those of most β-lactam antimicrobial agents.<unk>  is not metabolized to any significant extent and thus predominantly eliminated unchanged in the urine.<unk>  is partially metabolized to an inactive metabolite, and both drug and metabolite are excreted in the urine (80% as unchanged drug). The half-life of<unk>  is 2.5–3.0 hours, and the half-life of<unk>  is approximately 1.0 hour; the clearance of both drugs is directly proportional to renal function.<unk>  primarily undergoes renal excretion via active tubular secretion. Coadministration of<unk>  with<unk>  does not result in an interaction, since<unk>  is primarily eliminated by glomerular filtration.
Ceftolozane/tazobactam
Imipenem/cilastatin
Imipenem/cilastatin/relebactam
Ceftazidime/avibactam
Piperacillin/tazobactam
Ampicillin/sulbactam
Meropenem/vaborbactam
Tobramycin/dexamethasone